Stephen A. Strickland, Jr. Joins Transplant & Cellular Therapy Network as Director of Leukemia Research
NASHVILLE, TENN., August 25, 2022 - Sarah Cannon, the Cancer Institute of HCA Healthcare, announced today that Stephen A. Strickland, Jr., MD, MSCI, has been named the Director of Leukemia Research for the Sarah Cannon Transplant & Cellular Therapy Network. In his role, Dr. Strickland will provide scientific leadership and oversee Sarah Cannon’s robust portfolio of clinical trials in leukemia, myelodysplastic syndromes, and related diseases.
Dr. Strickland will join Sarah Cannon from Vanderbilt University Medical Center where he currently serves as the Clinical Director for Acute Leukemia and the Malignant Hematology and Stem Cell Transplant Medical Director.
“The Sarah Cannon Transplant & Cellular Therapy Network has a robust acute leukemia and myeloid disease clinical research program and cares for more than 1,800 leukemia patients yearly,” said Navneet Majhail, MD, MS, FASTCT, Deputy Physician-in-Chief of Blood Cancers for the Sarah Cannon Transplant & Cellular Therapy Network. “Dr. Strickland’s expertise and leadership within the acute leukemia field will further advance our mission to bring these novel therapies to our patients closer to home.”
Dr. Strickland is an internationally respected leukemia researcher with more than 100 peer-reviewed scientific publications and abstracts. He presently serves on several leukemia related committees within the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network.
He received his Doctor of Medicine from Louisiana State University School of Medicine in New Orleans and completed his internship/residency (Internal Medicine), clinical fellowship (Hematology/Oncology), and a Master of Science in Clinical Investigation at Vanderbilt University Medical Center.
In addition to his role with the Sarah Cannon Transplant & Cellular Therapy Network, Dr. Strickland will serve as Leukemia Specialist for the Sarah Cannon Transplant & Cellular Therapy Program at TriStar Centennial in Nashville, Tenn.
Dr. Strickland will begin his positions with the Sarah Cannon Transplant & Cellular Therapy Network and the Sarah Cannon Transplant & Cellular Therapy Program at TriStar Centennial on September 6, 2022.
About The Sarah Cannon Transplant & Cellular Therapy Network
The Sarah Cannon Transplant & Cellular Therapy Network offers adult and pediatric patients convenient and community-based access to treatments for blood cancer and blood and immune-related disorders, including hematopoietic cell transplantation and cellular therapy. Our Network of nine FACT/JACIE accredited transplant centers across the United States and United Kingdom treats more than 1,400 transplant and cellular therapy patients and 1,800 acute leukemia patient admissions annually. Emphasis is placed on providing high-quality research-based care with the opportunity for patients to enroll on innovative clinical trials. Our programs include Sarah Cannon Transplant & Cellular Therapy Program at St. David’s South Austin Medical Center in Austin, Medical City Dallas in Dallas, Colorado Blood Cancer Institute at Presbyterian/St. Luke’s Medical Center- HealthONE in Denver, Sarah Cannon Transplant & Cellular Therapy Program at Research Medical Center in Kansas City, Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital in Las Vegas, Sarah Cannon Transplant & Cellular Therapy Program at TriStar Centennial Medical Center in Nashville, Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital in San Antonio, HCA Healthcare UK at University College Hospital, Private Care (London), Private Care at Guy’s at London Bridge Hospital (London) and The Christie Private Care, part of HCA Healthcare UK (Manchester). For more information about the Network and Sarah Cannon’s full suite of oncology services, visit sarahcannon.com.